Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recanaclotide
- Development stage
- Discontinued
- Lead developer
- Ironwood Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
Recanaclotide is a synthetic peptide drug that acts as an agonist of the guanylate cyclase-C (GC-C) receptor. It was initially developed by Ironwood Pharmaceuticals for the treatment of gastrointestinal disorders such as functional dyspepsia and diabetic gastroparesis. The drug mimics the action of endogenous guanylin peptides by activating GC-C on intestinal epithelial cells, leading to increased cyclic GMP levels and promoting intestinal fluid secretion and motility. Recanaclotide reached Phase 2 clinical trials but its development has been discontinued[1][3][4].
- Other names
- RecanaclotidaCHEMBL3707244CHEMBL-3707244CHEMBL 3707244
02
Targets
GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on recanaclotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recanaclotide.